Prefer Dishman Among Midcap Pharma Stocks: Angel Broking

Mayuresh Joshi of Angel Broking says that Dishman Pharmaceuticals' Ebitda margins are expected to improve from the first quarter of FY16 on the back of commercial orders being executed.

Related Videos